Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The P2Y12 receptor is a G protein-coupled purinergic receptor primarily activated by adenosine diphosphate (ADP). It plays a critical role in platelet aggregation and is a key target for antithrombotic therapies. It is predominantly expressed on platelets, where it mediates ADP-induced platelet activation, and in the central nervous system, exclusively on microglia where it mediates neuroprotection. Pharmacological inhibition of P2Y12 leads to impaired platelet aggregation and is used to prevent thrombotic events.
P2Y12 receptor antagonists inhibit ADP-induced platelet activation and aggregation by blocking the binding of ADP to the P2Y12 receptor, which reduces adenylyl cyclase activity, leading to decreased cAMP levels and ultimately reduced platelet activation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P2Y purinoceptor 12 (P2Y12).